Bempedoic Acid and Ezetimibe
Nexlizet
Adenosine Triphosphate-Citrate Lyase Inhibitor
NADAC/unit
$13.8411
No Shortage
Tier 1: 15.5%
PA Req: 43.8%
vs. brand Nexlizet: Generic saves up to -38% per unit
Market Intelligence
2024-04-24 Class III Recall: Esperion
2023-09-13 Class III Recall: Esperion
Generic Manufacturers
ESPERION THERAPEUTICS INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.